Novo Nordisk faces US congressional grilling over price of weight loss drugs

Novo Nordisk's (NOVOb.CO) chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.